Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 116 clinical trials
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

found in only the half of the non-squamous NSCLC . More recently, immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and demonstrate an overall survival advantage over

ROS1
atezolizumab
durvalumab
pembrolizumab
serum bilirubin level
  • 0 views
  • 28 Feb, 2022
  • 1 location
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung

crizotinib
chronic hepatitis b
bevacizumab
ROS1
measurable disease
  • 25 views
  • 08 Aug, 2022
  • 439 locations
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

The phase 1 study is an open label, multi-center, non-randomized, dose escalation and expansion study designed to assess the safety, tolerability, and immunogenicity of IMU-201(PD1-Vaxx) as monotherapy in patients with PD-L1 expressing non-small cell lung cancer (NSCLC).

pd-1 inhibitor
measurable disease
lung cancer
pd-l1
lung carcinoma
  • 6 views
  • 23 Mar, 2022
  • 6 locations
A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers

Study LCB-1801-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NI-1801 in subjects with advanced, metastatic, or recurrent solid malignancies expressing mesothelin (MSLN). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses …

  • 0 views
  • 17 Jun, 2022
  • 1 location
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

. The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3

  • 0 views
  • 23 Mar, 2022
  • 1 location
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.

bladder tumor
measurable disease
formalin-fixed paraffin-embedded
lung cancer
sarcoma
  • 32 views
  • 14 Apr, 2022
  • 4 locations
Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer (LIBELULE)

Lung cancer is diagnosed at metastatic stage in 60% of the cases. For these patients, first-line treatment is based on histology and molecular characterization of non-squamous non-small cell

LKB1
ROS1
BRAF
lung cancer
c-MET
  • 1 views
  • 09 Feb, 2022
  • 14 locations
Research Trial to Study Safety of GEN1047 (DuoBody®-CD3xB7H4) in Participants With Malignant Solid Tumors

The drug that will be investigated in the study is an antibody, GEN1047. Since this is the first study of GEN1047 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN1047 dose to be tested in a larger group of participants and …

measurable disease
ovarian cancer
breast cancer
progressive disease
cancer
  • 1 views
  • 09 Aug, 2022
  • 6 locations
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

advanced or metastatic squamous non-small cell lung cancer. t the same time, Tislelizumab initial efficacy in patients with extensive small-cell lung cancr.Rational-206 study is a phase Ⅱ multi-cohort

Accepts healthy volunteers
chemoradiotherapy
nivolumab
platinum-based chemotherapy
anlotinib
  • 0 views
  • 14 Jul, 2022
  • 1 location
Sintilimab Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy and safety profile of sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens in advanced or metastatic NSCLC as first-line treatment. Totally 40 patients with negative driver genes (20 patients of squamous cell carcinoma, 20 patients …

  • 0 views
  • 18 Aug, 2021
  • 1 location